[1] 梁伟灿. 阿德福韦、恩替卡韦对慢性病毒性(乙型)肝炎治疗效果对比. 世界最新医学信息文摘, 2017, 17: 75-76. [2] Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology, 2009, 49: 1503-1514. [3] Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett, 2009, 286: 52-59. [4] Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl), 2009, 122: 3-4. [5] 王红梅, 刘珊珊. 乙肝后肝硬化失代偿期HBeAg阴性与阳性患者病毒学特点及肝功能指标的比较. 现代预防医学, 2015, 42: 2874-2877. [6] 刘文力. 阿德福韦酯与恩替卡韦治疗低病毒载量代偿期乙肝肝硬化疗效比较. 医学理论与实践, 2016, 29: 3051-3052. [7] 张莉, 张福奎. 恩替卡韦治疗慢性乙型肝炎进展. 世界华人消化杂志, 2017, 25: 7-16. |